Pain, Radiating Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 as Adjunctive Therapy in Subjects With Cancer-Related Pain, Followed by an Open-Label Extension Phase
The purpose of this study is to compare the safety and effectiveness of JNJ-42160443 with placebo in the treatment of chronic, moderate to severe cancer-related pain in terminally ill patients with a diagnosis of active cancer.
Status | Completed |
Enrollment | 100 |
Est. completion date | January 2015 |
Est. primary completion date | January 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 99 Years |
Eligibility |
Inclusion Criteria: - Terminally ill cancer patients as per judgment of the investigator (eg, patients who are in or who are candidates for hospice or palliative care for end-of-life management); Diagnosis of moderate to severe pain directly related to an active cancer that is not controlled by standard pain treatments. Exclusion Criteria:Planned major surgical procedures during the double-blind treatment phase that may affect study outcomes; Prior treatment with any other investigational NGF inhibitor therapy; Known allergies, hypersensitivity, or intolerance to JNJ-42160443 or its excipients; Enrolled in any investigational study within the previous 4 weeks or 5 half-lives of the investigational drug (whichever is longer), or are currently enrolled in another investigational study at the time of screening |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Janssen Research & Development, LLC |
United States, France, Poland, Portugal, Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The change in the average cancer-related pain intensity score. | From baseline (average cancer-related pain intensity score over the last 3 days before randomization) to the end of Week 4 (average cancer-related pain intensity score over the last 7 days of the double-blind treatment phase) | No | |
Secondary | Patient Global Impression of Change (PGIC) | Up to Visit 10 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03421951 -
Change in Pain and Quality of Life Following SCS for Chronic Pain
|
||
Completed |
NCT05307211 -
Are Stabilization Exercises Effective After Epidural Steroid Injection in Patients With Cervical Radiculopathy?
|
N/A | |
Suspended |
NCT02226159 -
Surgery Prevention by Transforaminal Injection of Epidural Steroids for Cervical Radicular Pain
|
Phase 4 | |
Completed |
NCT01831271 -
Neck-specific Training or Prescribed Physical Activity for Patients With Cervical Radiculopathy
|
N/A | |
Completed |
NCT03543085 -
Ultra-high Frequency (500 KHz) Spinal Cord Stimulation for Treatment of Chronic Back Pain or Lower Limb Pain
|
N/A |